Inter-rater and intra-rater agreement of [(99m)Tc]-labelled NM-01, a single-domain programmed death-ligand 1 (PD-L1) antibody, using quantitative SPECT/CT in non-small cell lung cancer

BACKGROUND: Immune checkpoint inhibitors, including those against programmed cell death protein-1 (PD-1) or its ligand (PD-L1), are routinely used to treat non-small cell lung cancer (NSCLC). PD-L1 is a validated prognostic and predictive immunohistochemical biomarker of anti-PD-1/PD-L1 therapy but...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, Daniel Johnathan, Chand, Gitasha, Johnson, Jessica, Bailey, Damion, Adamson, Kathryn, Goh, Vicky, Cook, Gary J. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232393/
https://www.ncbi.nlm.nih.gov/pubmed/37256434
http://dx.doi.org/10.1186/s13550-023-01002-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232393/
https://www.ncbi.nlm.nih.gov/pubmed/37256434
http://dx.doi.org/10.1186/s13550-023-01002-4

Ejemplares similares